OT-101
Phase 3Small molecule
OT-101 is one of 23 small molecule programs targeting Myopia. It is currently in Phase 3.
2
Indications
4
Total Trials
3
Active Trials
22
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
20 competitors in Myopia
#DrugCompanyPhaseTrials
1Atropen
FFresenius Kabi Taiwan Ltd.
Approved
Alphagan
NovartisApproved
Mitosol
UUroGen Pharma Ltd.
Approved
Isopto Carpine
AAdvanz Pharma
Approved
Oxylone
AbbVieApproved
Mydriacyl
FFalcon
Approved
Lotemax
PPharmos
Approved
Atropine Sulfate
FFresenius Kabi USA, LLC
Phase 3
OT-101
OOncotelic Inc.
Phase 3
Eylea
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Malignant Pleural Mesothelioma1 trial
COVID-191 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for OT-101. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- OOncotelic Inc.